RUNX transcription factors: biological functions and implications in cancer
- PMID: 38430423
- PMCID: PMC10908630
- DOI: 10.1007/s10238-023-01281-0
RUNX transcription factors: biological functions and implications in cancer
Abstract
Runt-related transcription factors (RUNX) are a family of transcription factors that are essential for normal and malignant hematopoietic processes. Their most widely recognized role in malignancy is to promote the occurrence and development of acute myeloid leukemia. However, it is worth noting that during the last decade, studies of RUNX proteins in solid tumors have made considerable progress, suggesting that these proteins are directly involved in different stages of tumor development, including tumor initiation, progression, and invasion. RUNX proteins also play a role in tumor angiogenesis, the maintenance of tumor cell stemness, and resistance to antitumor drugs. These findings have led to the consideration of RUNX as a tumor biomarker. All RUNX proteins are involved in the occurrence and development of solid tumors, but the role of each RUNX protein in different tumors and the major signaling pathways involved are complicated by tumor heterogeneity and the interacting tumor microenvironment. Understanding how the dysregulation of RUNX in tumors affects normal biological processes is important to elucidate the molecular mechanisms by which RUNX affects malignant tumors.
Keywords: Angiogenesis; Drug resistance; RUNX family; Signaling pathways; Tumor cell stemness; Tumor microenvironment.
© 2024. The Author(s).
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures



Similar articles
-
Roles of RUNX in Solid Tumors.Adv Exp Med Biol. 2017;962:299-320. doi: 10.1007/978-981-10-3233-2_19. Adv Exp Med Biol. 2017. PMID: 28299665 Review.
-
RUNX Family in Hypoxic Microenvironment and Angiogenesis in Cancers.Cells. 2022 Oct 1;11(19):3098. doi: 10.3390/cells11193098. Cells. 2022. PMID: 36231060 Free PMC article. Review.
-
RUNX family: Oncogenes or tumor suppressors (Review).Oncol Rep. 2019 Jul;42(1):3-19. doi: 10.3892/or.2019.7149. Epub 2019 May 6. Oncol Rep. 2019. PMID: 31059069 Free PMC article. Review.
-
Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation.Gene. 2006 Jan 17;366(1):58-66. doi: 10.1016/j.gene.2005.10.017. Epub 2005 Dec 1. Gene. 2006. PMID: 16325352 Review.
-
RUNX Proteins as Epigenetic Modulators in Cancer.Cells. 2022 Nov 20;11(22):3687. doi: 10.3390/cells11223687. Cells. 2022. PMID: 36429115 Free PMC article. Review.
Cited by
-
CBFβ Regulates RUNX3 ADP-Ribosylation to Mediate Homologous Recombination Repair.J Cell Physiol. 2025 Jan;240(1):e31503. doi: 10.1002/jcp.31503. Epub 2024 Dec 18. J Cell Physiol. 2025. PMID: 39696918
-
Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance.Int J Mol Sci. 2025 Aug 7;26(15):7642. doi: 10.3390/ijms26157642. Int J Mol Sci. 2025. PMID: 40806771 Free PMC article. Review.
-
Identification of cancer-associated fibroblast subtypes and prognostic model development in breast cancer: role of the RUNX1/SDC1 axis in promoting invasion and metastasis.Cell Biol Toxicol. 2025 Jan 3;41(1):21. doi: 10.1007/s10565-024-09950-w. Cell Biol Toxicol. 2025. PMID: 39753834 Free PMC article.
References
-
- Chuang LS, Ito K, Ito Y. RUNX family: regulation and diversification of roles through interacting proteins. Int J Cancer. 2013;132(6):1260–71. - PubMed
-
- Durst KL, Hiebert SW. Role of RUNX family members in transcriptional repression and gene silencing. Oncogene. 2004;23(24):4220–4. - PubMed
-
- Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O. The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation. Cancer Cell. 2018;34(4):626–42. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical